SANTA
CLARA, Calif., Aug. 31,
2023 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a company that develops, manufactures and markets innovative
medical products and services that assist in evaluating and
treating chronic diseases, today announced Renae Cormier, CFO, will participate in the
following investor conference:
Lake Street Capital Markets 7th Annual Best Ideas
Growth (BIG7) Conference
Date: September 14, 2023
Format: One-on-one meetings
About Semler Scientific, Inc.:
Semler Scientific,
Inc. develops, manufactures and markets innovative products and
services that assist in evaluating and treating chronic diseases.
Its flagship product, QuantaFlo®, which is patented and cleared by
the U.S. Food and Drug Administration (FDA), is a rapid
point-of-care test that measures arterial blood flow in the
extremities. The QuantaFlo® test aids in the diagnosis of
cardiovascular diseases, such as peripheral arterial disease (PAD)
and heart dysfunction (HD). QuantaFlo® is used by healthcare
providers to evaluate their patient's risk of mortality and major
adverse cardiovascular events (MACE). In addition, Semler
Scientific has an agreement with Mellitus Health, Inc. (Mellitus)
to exclusively market and distribute Insulin Insights™, an
FDA cleared software product that recommends optimal insulin dosing
for diabetic patients in the United
States, including Puerto
Rico. Semler Scientific has a minority investment in
Mellitus, as well as Monarch Medical Technologies LLC, a privately
held company whose product EndoTool® offers a technological
solution for inpatient glycemic management. Additional information
about Semler Scientific can be found at
www.semlerscientific.com.
CONTACT:
Renae
Cormier
Chief Financial Officer
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-to-present-at-upcoming-investor-conference-301915275.html
SOURCE Semler Scientific, Inc.